- Home
- LSBK vs CTMX Comparison
LSBK vs CTMX Comparison
Compare LSBK & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSBK
- CTMX
- Stock Information
- Founded
- LSBK 1891
- CTMX 2008
- Country
- LSBK United States
- CTMX United States
- Employees
- LSBK N/A
- CTMX N/A
- Industry
- LSBK Savings Institutions
- CTMX Biotechnology: Pharmaceutical Preparations
- Sector
- LSBK Finance
- CTMX Health Care
- Exchange
- LSBK Nasdaq
- CTMX Nasdaq
- Market Cap
- LSBK 91.1M
- CTMX 62.3M
- IPO Year
- LSBK 2006
- CTMX 2015
- Fundamental
- Price
- LSBK $15.80
- CTMX $0.80
- Analyst Decision
- LSBK
- CTMX Buy
- Analyst Count
- LSBK 0
- CTMX 6
- Target Price
- LSBK N/A
- CTMX $5.77
- AVG Volume (30 Days)
- LSBK 4.1K
- CTMX 731.5K
- Earning Date
- LSBK 01-24-2025
- CTMX 03-10-2025
- Dividend Yield
- LSBK 4.56%
- CTMX N/A
- EPS Growth
- LSBK 7.32
- CTMX N/A
- EPS
- LSBK 0.88
- CTMX 0.16
- Revenue
- LSBK $25,846,000.00
- CTMX $126,617,000.00
- Revenue This Year
- LSBK N/A
- CTMX $22.55
- Revenue Next Year
- LSBK N/A
- CTMX N/A
- P/E Ratio
- LSBK $17.95
- CTMX $4.93
- Revenue Growth
- LSBK N/A
- CTMX 33.66
- 52 Week Low
- LSBK $10.30
- CTMX $0.75
- 52 Week High
- LSBK $16.56
- CTMX $5.85
- Technical
- Relative Strength Index (RSI)
- LSBK 64.39
- CTMX 41.61
- Support Level
- LSBK $15.51
- CTMX $0.75
- Resistance Level
- LSBK $16.56
- CTMX $0.98
- Average True Range (ATR)
- LSBK 0.42
- CTMX 0.06
- MACD
- LSBK 0.08
- CTMX 0.00
- Stochastic Oscillator
- LSBK 75.95
- CTMX 20.13
About LSBK Lake Shore Bancorp Inc.
Lake Shore Bancorp Inc operates as a savings and loan holdings company. The bank's business consists of attracting retail deposits from the general public in the areas surrounding its branch offices and investing those deposits, together with funds generated from operations, in commercial real estate loans, one-to-four family residential mortgage loans, home equity lines of credit and, to a lesser extent, commercial business loans, consumer loans, and investment securities. Its revenues are principally derived from interest earned on loans and investment securities.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.